Aptamer Group develops Optimer® binders to enable innovation in the life science industry. Optimer binders are oligonucleotide-based affinity binders for use in research, diagnostics, therapeutics and bioprocessing. Combining high target affinity and selectivity, with an expanded target range and the highest batch consistency the fully in vitro Optimer discovery and development platform is supporting new and improved solutions.
Location: United Kingdom, England, Heslington
Member count: 11-50
Total raised: $4.630147M
Founded date: 2008
Investors 1
| Date | Name | Website |
| - | Meneldor | meneldor.n... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 31.07.2023 | IPO | $4.630147M | - | eustartup.... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 31.07.2023 | Aptamer Group Scoops £3.6M in Recent Post-IPO Equity Fundrai... | Key Takeaways: Aptamer Group, a biotechnology startup, has raised £3.6 million in a recent funding r... | eustartup.... |
| 22.12.2021 | Aptamer IPO: the next Biotech stock to watch? | Biotech stock Aptamer is launching its IPO on 22 December. Is this the next Biotech stock to watch? ... | cityam.com... |
| 25.08.2021 | Aptamer Group and Bio-Works Technologies partner to enable i... | Aptamer Group and Bio-Works Technologies partner to enable improved solutions for gene therapy manuf... | news.cisio... |